Generic Name and Formulations:
Somatropin (rDNA origin) 4mg, 5mg, 6mg; per vial; for SC inj after reconstitution.
EMD Serono, Inc.
Indications for SEROSTIM:
HIV patients with wasting or cachexia to increase lean body mass and weight, and improve physical endurance.
Give by SC inj once daily at bedtime. Rotate inj sites. <35kg: 0.1mg/kg. 35–45kg: 4mg. 45–55kg: 5mg. >55kg: 6mg. Risk factors for adverse effects (eg, glucose intolerance): initially 0.1mg/kg every other day.
Not established; see full labeling.
Acute critical illness due to surgical complications or multiple accidental trauma or those with acute respiratory failure. Active malignancy. Active proliferative or severe non-proliferative diabetic retinopathy.
Increased mortality in those with acute critical illness (see Contraindications). Use only under guidance of a physician trained in HIV management. HIV patients should be maintained on antiretroviral therapy. Glucose intolerance. Diabetes. Perform baseline and periodic funduscopic evaluation for intracranial hypertension; discontinue if papilledema occurs; may restart at lower dose after resolution. Monitor for development, progression, or recurrence of neoplasms. Discontinue if carpal tunnel syndrome persists after dosage reduction. Turner syndrome. Elderly. Pregnancy (Cat.B). Nursing mothers.
May be antagonized by glucocorticoids. May affect CYP450 substrates (eg, corticosteroids, sex steroids, anticonvulsants, cyclosporine); monitor. Concomitant oral estrogens; may require larger somatropin doses. Concomitant insulin and/or hypoglycemics may require dose adjustment.
Growth hormone (GH).
Musculoskeletal discomfort, increased tissue turgor, edema, nausea, fatigue, gynecomastia, paresthesia, hypoesthesia, hyperglycemia, hypertriglyceridemia, carpal tunnel syndrome; intracranial hypertension, serious hypersensitivity reactions; rare: pancreatitis.
Single-dose vials (5mg, 6mg)—7 (w. diluent); Multi-dose vials (4mg)—7 (w. diluent)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|